{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/68112e9e6ac0e5213b5194c2/68716522b6e89a41282041b5?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Big Pharma’s big tariffs ","description":"<p>When US President Donald Trump threatened 200 per cent tariffs on foreign-made pharmaceuticals, investors responded like it was a placebo. It’s the latest spat between drugmakers and an administration that share a complicated relationship. The FT’s Hannah Kuchler and Patrick Temple-West explain why Trump and Big Pharma aren’t getting along, and what that prescribes for the future of the industry.</p><p><br></p><p>Mentioned in this podcast:</p><p><a href=\"https://mail.google.com/mail/?view=cm&amp;fs=1&amp;tf=1&amp;to=marc.filippino@ft.com\" rel=\"noopener noreferrer\" target=\"_blank\">Email Marc your questions</a> (Marc.Filippino@ft.com)</p><p><a href=\"https://www.ft.com/content/f59f04f1-666f-4c7f-8054-43e00322811e\" rel=\"noopener noreferrer\" target=\"_blank\">Investors shrug off Donald Trump’s 200% tariff on pharma</a></p><p><a href=\"https://www.ft.com/content/360cb65b-a9ab-4fed-b8b3-7c34f2560938\" rel=\"noopener noreferrer\" target=\"_blank\">The looming ‘patent cliff’ facing Big Pharma</a></p><p><a href=\"https://ep.ft.com/newsletters/56a64b704f693a0300dfab7e/subscribe\" rel=\"noopener noreferrer\" target=\"_blank\">Sign up for the FT’s Swamp Notes newsletter here</a></p><p><br></p><p>Swamp Notes is produced by Henry Larson. Topher Forhecz is the FT’s executive producer. The FT’s acting co-head of audio is Topher Forhecz. Special thanks to Pierre Nicholson.&nbsp;</p><p><br></p><p>CREDIT: The White House, Roll Call</p><p><br></p><p><a href=\"https://www.ft.com/content/4d941e63-318f-48c4-8ef9-7f335214f038\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Read a transcript of this episode on FT.com</strong></a></p>","author_name":"Financial Times"}